Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8654924 | 1.00 | TK1 (0.65) | TK1POLB | |
| Triphosphate SCHEMBL6046309 | 0.90 | POLB (0.68) | TK1POLB | |
| SCHEMBL655193 | 0.90 | TK1 (0.67) | TK1POLB | |
| Doxribtimine SCHEMBL767986 | 0.89 | TK1 (0.73) | TK1 | |
| SCHEMBL19224119 | 0.89 | TK1 (0.69) | TK1POLB | |
| SCHEMBL14063727 | 0.89 | TK1 (0.69) | TK1POLB | |
| SCHEMBL12352406 | 0.89 | TK1 (0.69) | TK1POLB | |
| Doxribtimine SCHEMBL21078835 | 0.89 | TK1 (0.73) | TK1 | |
| Doxribtimine SCHEMBL2722555 | 0.89 | TK1 (0.73) | TK1 | |
| Doxribtimine SCHEMBL10382149 | 0.89 | TK1 (0.73) | TK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 222 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024011146-A1 | A SYNTHETIC PROTEIN-LEVEL NEURAL NETWORK IN MAMMALIAN CELLS | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2024-01-11 | — | — | WO | claimed |
| CN-109312313-A | For treating the mRNA therapy of ornithine transcarbamylase deficiency disease | 川斯勒佰尔公司 | 2019-02-05 | — | — | CN | claimed |
| CN-106413811-A | MRNA therapy for deficiency of argininosuccinate synthetase | 夏尔人类遗传性治疗公司 | 2017-02-15 | — | — | CN | claimed |
| US-8609677-B2 | Molecules for the photodynamic treatment of tumors and hyperplasias | Yagna Limited (GB) | 2013-12-17 | — | — | US | claimed |
| US-20130226136-A1 | Molecules for the Photodynamic Treatment of Tumors and Hyperplasias | HUMANITARIAN SCIENTIFIC LLC | 2013-08-29 | — | — | US | claimed |
| US-20260103707-A1 | NOVEL COMPOUND AND APPLICATION THEREOF | KYLONOVA XIAMEN BIOPHARMA CO LTD (CN) | 2026-04-16 | — | — | US | disclosed |
| US-12516317-B1 | Binding and catalytic molecules built from expanded DNA | BENNER STEVEN A (US) | 2026-01-06 | — | — | US | disclosed |
| WO-2025264548-A2 | MODIFIED POLYNUCLEIC ACID MOLECULES TARGETING AGT AND USES THEREOF | SIRIUS THERAPEUTICS, INC. (US) | 2025-12-26 | — | — | WO | disclosed |
| EP-4665405-A1 | DNA COMPOSITIONS COMPRISING MODIFIED URACIL | Flagship Pioneering Innovations VII, LLC (US) | 2025-12-24 | — | — | EP | disclosed |
| WO-2025235375-A1 | COMPOSITIONS AND METHODS FOR CONTROLLING CELLULAR RESPONSES | THE CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2025-11-13 | — | — | WO | disclosed |
| US-20250241848-A1 | NANOPARTICLE COMPOSITIONS, FORMULATIONS THEREOF, AND USES THEREFOR | ANTERIOS, INC. (US) | 2025-07-31 | — | — | US | disclosed |
| WO-2025088373-A1 | COMPOSITIONS AND METHODS OF MODULATING LONG NONCODING TRANSCRIPTS ASSOCIATED WITH ARDS INDUCED PULMONARY FIBROSIS | HAYA THERAPEUTICS SA (CH) | 2025-05-01 | — | — | WO | disclosed |
| US-5145840-A | Treatment of virac and bacterial infections; aids | BURROUGHS WELLCOME CO. (US) | 1992-09-08 | — | — | US | disclosed |
| EP-0498843-A1 | OLIGONUCLEOTIDE ANALOGS WITH NOVEL LINKAGES. | GILEAD SCIENCES INC (US) | 1992-08-19 | — | — | EP | disclosed |
| US-5064946-A | 3-azido-2,3-dideoxy-B-D-erythro-pentofuranosyl derivatives of 4(1H)-pyrimidinones; antiretroviral, anti-AIDS | BURROUGHS WELLCOME CO. (US) | 1991-11-12 | — | — | US | disclosed |
| WO-1991006629-A1 | OLIGONUCLEOTIDE ANALOGS WITH NOVEL LINKAGES | GILEAD SCIENCES, INC. (US) | 1991-05-16 | — | — | WO | disclosed |
| WO-1991004982-A1 | FURTHER ANTIVIRAL PYRIMIDINE NUCLEOSIDES | UNIVERSITY OF BIRMINGHAM (GB) | 1991-04-18 | — | — | WO | disclosed |
| EP-0422090-A1 | DERIVATIVES OF NUCLEOSIDES WHICH MAY BE USED FOR THE SYNTHESIS OF MARKED OLIGONUCLEOTIDES, AND OLIGONUCLEOTIDES OBTAINED FROM THESE DERIVATIVES AND THEIR SYNTHESIS. | CIS BIO INT (FR) | 1991-04-17 | — | — | EP | disclosed |
| WO-1989012642-A1 | DERIVATIVES OF NUCLEOSIDES WHICH MAY BE USED FOR THE SYNTHESIS OF MARKED OLIGONUCLEOTIDES, AND OLIGONUCLEOTIDES OBTAINED FROM THESE DERIVATIVES AND THEIR SYNTHESIS | CIS BIO INTERNATIONAL (FR) | 1989-12-28 | — | — | WO | disclosed |
| EP-0217580-A2 | Therapeutic nucleosides | THE WELLCOME FOUNDATION LIMITED (GB) | 1987-04-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250241848-A1 | NANOPARTICLE COMPOSITIONS, FORMULATIONS THEREOF, AND USES THEREFOR | TSG101, NPC1L1, NPC1 | TK1 1670/4885POLB 3385/4885 |
| US-20260103707-A1 | NOVEL COMPOUND AND APPLICATION THEREOF | GALNT10, FUT5, FUT6 | TK1 1033/4885POLB 1725/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.